Decipher by Veracyte

More than a dozen posters and podium talks were presented at the latest #AUA2024 meeting discussing the power of Veracyte, Inc.'s Decipher Prostate and Bladder tests, as well as our and Decipher GRID (Genomics Resource for Intelligent Discovery) transcriptomic database. Among these was a study discussing that patients with low and intermediate risk #ProstateCancer (GGG 1-3 on initial biopsy), the Decipher Score is a predictor of clinically significant upgrading (i.e, increase in GGG) on final radical prostatectomy pathology. Click the link below to read an overview of this presentation: https://lnkd.in/gRvB8GHv

Join us from July 10-13 in National Harbor, Maryland, for the 2024 World Congress of Brachytherapy. Visit the @Veracyte #Decipher team to learn how we support patients with #ProstateCancer. #WCB2024

ICYMI: As presented at #AUA2024, Decipher testing reveals biologic differences between prostate cancer lesions based on their zonal location (PZ or TZ) within the prostate gland. Zonal location and lesion size were independently associated with Decipher score, and gene expression differences between TZ and PZ lesions were identified. Follow the link to read more. https://lnkd.in/gWzbwVTk

We will be attending the NYU Advances in Screening, Detection, & Treatment of Prostate Cancer meeting, in New York, NY, on June 28-29! If you're here, stop by our booth and speak with our team to learn how Veracyte, Inc.'s Decipher Prostate Genomic Classifier can help provide clarity and confidence for treatment planning.

Veracyte, Inc.'s Decipher Prostate Genomic Classifier is thrilled to be part of UroToday's new online Center of Excellence. Follow the link below to view their collection of insights, resources, and advancements in the field of urology.

Meet Amanda, a dedicated Customer Experience Manager providing valuable support to our Northeast sales region! As a well-deserved "Rookie of the Year" recipient, Amanda has demonstrated outstanding resilience and adaptability, overcoming challenges with grace and determination. Her commitment to growth, paired with her warm sense of humor, make her a true asset to our team. We're proud of her accomplishments and look forward to her continued success at Veracyte, Inc.!

Save the date! Veracyte, Inc.'s #Decipher Team will be at the Washington State Urology Society Annual Conference, in Stevenson, WA on June 21-23. Stop by our booth to discuss how we are changing #ProstateCancer patient care.

ICYMI: Featured at the #AUA2024 meeting was a study assessing Veracyte, Inc.'s Decipher Prostate Score vs. PSA in predicting the risk of metastatic progression post-prostatectomy for Grade Group 1 or 2 prostate cancer patients, highlighting Decipher Score as a better predictor of distant metastasis. Follow the link to learn more: https://lnkd.in/ginHgY8b #ProstateCancer

ICYMI: Data from #AUA2024 analyzed the association of patients pre-treatment Decipher Prostate score in predicting cancer upgrading. In an assessment of 104 patients, they found that Veracyte, Inc.'s Decipher Prostate score was significantly associated with upgrading on radical prostatectomy. Follow the link below to read more: https://lnkd.in/gSckJ-Za

Veracyte, Inc.'s, Decipher is celebrating #MensHealthWeek2024 from June 10-16! This annual event aims to raise awareness of health issues, like prostate cancer, and promote early detection and treatment. For those with #ProstateCancer, Decipher Prostate provides information to help physicians and their patients make informed treatment decisions.